北京市春立正达医疗器械股份有限公司 2025 年度提质增效重回报专项行动方案的 固定板系统等产品注册证。上述脊柱产品注册证的取得完善了公司脊柱系列产品线，进 一步提高公司在脊柱骨科行业的市场竞争力。 运动医学领域，公司取得了聚醚醚酮敲入式免打结锚钉、可调节带袢钛板、聚醚醚 酮带线锚钉等产品注册证，进一步丰富了公司运动医学产品线，公司在运动医学领域的 布局更加完善，齐备的运动医学产品线利于临床的选用。 创伤领域，公司在积极研发创伤业务领域的产品。截至 2025 年 6 月 30 日，公司创 伤系列产品已有多款产品获批上市，包括接骨板、髓内钉、外固定支架、金属骨针、空 心接骨螺钉、钛网板系统等，进一步补充了公司的骨科业务产品线。 半年度评估报告 为践行以"投资者为本"的上市公司发展理念，维护公司全体股东的利益，基于对 经营状况和未来发展前景的信心，围绕立足主业、提升科技创新水平、回报股东、加强 投资者沟通等方面，北京市春立正达医疗器械股份公司（以下简称"公司"或"春立医 疗"）于 2025 年 5 月 28 日发布了《2025 年度"提质增效重回报"专项行动方案》（以 下简称"行动方案"），以进一步优化经营效率、 ...

证券代码：688236 证券简称：春立医疗 公告编号：2025-039 北京市春立正达医疗器械股份有限公司 关于计提 2025 年半年度资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日召开第五届董事会第二十六次会议、第五届监事会第十八次会议，审议 通过了《关于计提 2025 年半年度资产减值准备的议案》。 现将相关具体情况公告如下： 一、计提减值准备的情况概述 对于其他应收款，本公司则根据款项的性质，将其划分为具有不同信用风险 特征的组合，再针对每个组合，综合考虑各类款项的回收风险特点、历史回收情 况等因素，在组合基础上计算相应的预期信用损失。 2025 年半年度，公司以预期信用损失为基础，对应收账款、其他应收款进行 减值测试，计提信用减值损失 12,418,491.12 元。 （二）资产减值损失 资产负债表日，存货按照成本与可变现净值孰低计量，当期可变现净值低于 成本时，提取存货跌价准备，并按单个存货项目计提存货跌 ...

Core Viewpoint - The stock of Chunli Medical (688236) has experienced a decline, with a closing price of 21.92 yuan on August 27, 2025, down by 2.97% [1] Group 1: Stock Performance and Trading Data - On August 27, 2025, the stock had a turnover rate of 0.82%, with a trading volume of 23,600 lots and a transaction amount of 53.18 million yuan [1] - The net outflow of main funds was 2.87 million yuan, accounting for 5.4% of the total transaction amount, while retail investors saw a net inflow of 2.20 million yuan, representing 4.13% of the total [1][2] - Over the past five days, the stock has seen fluctuations in fund flows, with significant net inflows and outflows from different investor categories [2] Group 2: Financial Metrics and Industry Comparison - Chunli Medical's total market value is 8.408 billion yuan, which is below the industry average of 12.081 billion yuan, ranking 45th out of 123 in the medical device sector [3] - The company reported a net profit of 58.07 million yuan for the first quarter of 2025, reflecting a year-on-year increase of 5.2%, with a gross margin of 66.69% [3] - The company's price-to-earnings ratio (P/E) stands at 36.2, significantly lower than the industry average of 72.56, ranking 43rd out of 123 [3] Group 3: Analyst Ratings - In the last 90 days, two institutions have issued buy ratings for Chunli Medical, indicating positive sentiment among analysts [4]

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a slight decline in stock price and notable financing activities on August 26 [1] - On August 26, Spring Medical's stock price decreased by 0.70%, with a trading volume of 51.21 million yuan, and a net financing purchase of 2.68 million yuan [1] - As of August 26, the total balance of margin trading for Spring Medical was 43.59 million yuan, which accounts for 0.67% of its market capitalization, indicating a high level compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products being joint prosthetics and spinal implants [2] - The company reported a revenue of 230 million yuan for the first quarter of 2025, reflecting a year-on-year growth of 3.60%, and a net profit attributable to shareholders of 58.07 million yuan, up by 5.20% [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 3 - As of March 31, 2025, the number of shareholders for Spring Medical increased by 7.48% to 7,182, while the average circulating shares per person decreased by 6.99% to 11,063 shares [2] - Among the top ten circulating shareholders, Zhonggeng Small Cap Value Stock holds 2.87 million shares, remaining unchanged, while Hong Kong Central Clearing Limited increased its holdings by 1.11 million shares to 2.29 million shares [3] - New shareholders include Ping An Low Carbon Economy Mixed A, which holds 1 million shares, while some funds exited the top ten circulating shareholders list [3]

Core Viewpoint - The stock of Chunli Medical (688236) has shown a slight increase, with a closing price of 22.75 yuan on August 25, 2025, reflecting a 0.35% rise, while the overall market sentiment indicates mixed fund flows [1][2]. Fund Flow Summary - On August 25, 2025, the net outflow of main funds was 435.19 million yuan, accounting for 7.46% of the total transaction amount, while retail investors saw a net inflow of 481.9 million yuan, representing 8.27% of the total [1][2]. - Over the past five days, the fund flow data shows fluctuations, with significant net outflows from main funds on August 22 (2008.72 million yuan) and August 21 (252.93 million yuan), while retail investors had notable inflows on those days [2]. Company Performance Metrics - Chunli Medical's total market value is 8.726 billion yuan, with a net asset value of 2.879 billion yuan and a net profit of 58.071 million yuan, ranking 45th, 52nd, and 42nd respectively in the medical device industry [3]. - The company reported a gross margin of 66.69% and a net margin of 25.25%, both of which are significantly higher than the industry averages of 51.33% and 10.71% respectively [3]. - In the first quarter of 2025, the company's main revenue was 230 million yuan, showing a year-on-year increase of 3.6%, while the net profit increased by 5.2% [3]. Industry Ratings - In the last 90 days, three institutions have issued buy ratings for Chunli Medical, indicating positive sentiment towards the stock [4].

公司公告汇总 春立医疗（证券代码：688236）将于2025年9月1日（星期一）上午10:00-11:00举行2025年半年度业绩说 明会。会议将在上海证券交易所上证路演中心以网络互动形式召开。公司计划在2025年8月30日发布 2025年半年度报告，为让投资者更全面深入地了解公司经营成果和财务状况，将针对2025年半年度的经 营成果及财务指标与投资者进行互动交流。出席人员包括董事长史文玲女士、总经理史春生先生、财务 总监卢宏悦女士和董事会秘书解凤宝先生。投资者可在2025年9月1日上午10:00-11:00通过互联网登录上 证路演中心在线参与，也可在2025年8月25日至8月29日16:00前登录上证路演中心网站首页点击"提问预 征集"栏目或通过公司邮箱ir@clzd.com提问。联系人：公司证券部，电话：010-87321998，邮箱： ir@clzd.com。投资者可通过上证路演中心查看本次投资者说明会的召开情况及主要内容。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 截至2025年8月22日收盘，春立医疗（688236） ...

Group 1 - The core point of the article highlights the financing activities of Chunli Medical, indicating a net sell-off in recent trading days [1] - On August 22, Chunli Medical had a financing buy-in amount of 0.15 billion, ranking 1288th in the market, with a financing repayment amount of 0.16 billion, resulting in a net sell-off of 0.8917 million [1] - Over the last three trading days (August 20-22), Chunli Medical recorded financing buy-ins of 0.13 billion, 0.07 billion, and 0.15 billion respectively [1] Group 2 - In terms of securities lending, on August 22, there were no shares sold or net sold in the securities lending market for Chunli Medical [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688236 证券简称：春立医疗 公告编号：2025-034 北京市春立正达医疗器械股份有限公司 关于召开2025年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025年9月1日（星期一） 上午 10:00-11:00 会议召开地点：上海证券交易所上证路演中心（https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年8月25日（星期一）至8月29日（星期五）16:00前登录上证路演中心网站首页点击"提 问预征集"栏目或通过公司邮箱ir@clzd.com进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 北京市春立正达医疗器械股份有限公司（以下简称"公司"）将于2025年8月30日发布公司2025年半年度 报告，为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年 9月1日上午10:00-11:00举行 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立 正達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《北京市春立正達醫療器械股份有 限公司關於召開2025年半年度業績說明會的公告》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2025年8月22日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生； 本公司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 ...

Core Points - The company, Beijing Chunli Zhengda Medical Devices Co., Ltd., will hold a half-year performance briefing on September 1, 2025, from 10:00 to 11:00 AM [1][2] - The briefing will be conducted in an interactive online format via the Shanghai Stock Exchange Roadshow Center [2][3] - Investors can submit questions for the briefing from August 25 to August 29, 2025, before 4:00 PM [3] Summary by Sections Meeting Details - The performance briefing is scheduled for September 1, 2025, from 10:00 to 11:00 AM [1][2] - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [1][2] - The meeting will be held in an interactive format, allowing for real-time communication with investors [2] Participation Information - Investors can participate by logging into the Shanghai Stock Exchange Roadshow Center on the day of the event [2][3] - Questions can be pre-submitted through the Roadshow Center's website or via the company's email from August 25 to August 29, 2025 [3] Contact Information - The company’s contact for inquiries is the Securities Department, reachable at phone number 010-87321998 or via email at ir@clzd.com [3]